CryoPort (NASDAQ:CYRX) Releases Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• CryoPort reported $48.97 million in quarterly revenue, exceeding the $48.18 million consensus estimate, while adjusted EPS of negative $0.20 missed expectations by $0.01.
• The company achieved positive adjusted EBITDA of $400,000 and generated about $5 million in operating cash flow during the first half, supported by growth across its life-sciences and cell-and-gene-therapy businesses.
• CryoPort reaffirmed 2026 revenue guidance of $192 million to $196 million; analysts remain generally bullish, with a consensus “Moderate Buy” rating and an average price target of $18.

CryoPort (NASDAQ:CYRX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01), Zacks reports. CryoPort had a negative return on equity of 7.13% and a negative net margin of 20.05%.The company had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million.

Here are the key takeaways from CryoPort's conference call:

• Revenue reached $49 million in the second quarter, with Life Sciences Services revenue up 15% year over year, commercial cell and gene therapy support revenue up 9%, and clinical-trial support revenue up 12%.
• Cryoport achieved positive adjusted EBITDA of $400,000, a $1.3 million year-over-year improvement, and generated approximately $5 million of operating cash flow in the first half, supporting management’s path toward sustainable profitability.
• The company’s pipeline remains broad, with 779 clinical trials supported globally, 22 commercial cell and gene therapies, and expectations for 11 potential BLA/MAA filings, five new therapy approvals, and one label or geographic expansion during the remainder of 2026.
• Cryoport reaffirmed its 2026 continuing-operations revenue guidance of $192 million to $196 million rather than raising it, citing geopolitical and macroeconomic uncertainty despite strong underlying demand.
• New growth initiatives—including IntegriCell cryopreservation services, the Fusion 811 freezer, China-based manufacturing, and new supply-chain facilities in Paris and Santa Ana—are expected to expand future capacity, although IntegriCell is not expected to contribute significantly to 2026 revenue.

CryoPort Stock Performance

Shares of CryoPort stock traded up $0.41 on Friday, hitting $15.12. 1,069,240 shares of the company's stock traded hands, compared to its average volume of 609,580. The firm's 50-day moving average price is $15.50 and its two-hundred day moving average price is $11.89. CryoPort has a one year low of $7.51 and a one year high of $16.89.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CYRX shares. KeyCorp increased their price objective on CryoPort from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded CryoPort from a "sell" rating to a "hold" rating in a research report on Monday, May 11th. Needham & Company LLC upped their price target on CryoPort from $15.00 to $19.00 and gave the company a "buy" rating in a research note on Friday. BTIG Research raised their price target on CryoPort from $17.00 to $25.00 and gave the company a "buy" rating in a report on Friday, July 24th. Finally, Roth Capital reiterated a "buy" rating and issued a $21.00 price objective on shares of CryoPort in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, CryoPort has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Key CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

Insider Transactions at CryoPort

In other CryoPort news, insider Edward J. Zecchini sold 33,600 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the transaction, the insider owned 109,719 shares of the company's stock, valued at approximately $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert Stefanovich sold 169,427 shares of the firm's stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the transaction, the chief financial officer owned 109,850 shares in the company, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 227,641 shares of company stock worth $3,622,515 in the last three months. Insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. LPL Financial LLC raised its position in CryoPort by 6.6% during the fourth quarter. LPL Financial LLC now owns 23,306 shares of the company's stock worth $224,000 after acquiring an additional 1,433 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of CryoPort by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company's stock valued at $136,000 after acquiring an additional 1,557 shares during the period. State of Wyoming grew its position in shares of CryoPort by 30.2% in the 2nd quarter. State of Wyoming now owns 14,218 shares of the company's stock valued at $106,000 after acquiring an additional 3,301 shares during the period. BNP Paribas Financial Markets increased its stake in shares of CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company's stock worth $113,000 after purchasing an additional 4,225 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares during the last quarter. Institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source